Metraipolis › archive › dc_ea5936c857f6

Optimizing Anti-PD1 Immunotherapy: An Overview of Pharmacokinetics, Biomarkers, and Therapeutic Drug Monitoring — Europe PMC PMID:41097788

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41097788
DOI
10.3390/cancers17193262
License (as archived)
solo-consultazione
Archived
2026-11-09T11:38:31.459Z
SHA-256 of the archived text
ead582ec26dd73acb61f510a5334319d82f1e8f938b4deb01e22e44e34ec670f
Stable URL of this page
https://metraipolis.com/documento/dc_ea5936c857f6

How to cite

Optimizing Anti-PD1 Immunotherapy: An Overview of Pharmacokinetics, Biomarkers, and Therapeutic Drug Monitoring — Europe PMC PMID:41097788 — Europe PMC (en), https://europepmc.org/article/MED/41097788 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ea5936c857f6 (Metraipolis archive dc_ea5936c857f6, sha256 ead582ec26dd73acb61f510a5334319d82f1e8f938b4deb01e22e44e34ec670f)
BibTeX
@misc{dcea5936c857f6,
  title = {Optimizing Anti-PD1 Immunotherapy: An Overview of Pharmacokinetics, Biomarkers, and Therapeutic Drug Monitoring — Europe PMC PMID:41097788},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41097788},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ea5936c857f6; sha256 ead582ec26dd73acb61f510a5334319d82f1e8f938b4deb01e22e44e34ec670f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41097788. Agents can read the archived copy with the MCP tool read_document.